John Lechleiter, Eli Lilly chairman & CEO breaks down his company's earnings results of an adjusted $0.92 a share versus estimates of $0.78 est. and a look at the drug maker's generic challenges, and the politics of prescriptions.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT